{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:42:56Z","timestamp":1761864176476,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.urolonc.2020.08.032","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T13:28:27Z","timestamp":1600349307000},"page":"191.e17-191.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The suggested chemopreventive association of metformin with prostate cancer in diabetic patients"],"prefix":"10.1016","volume":"39","author":[{"given":"Hanan","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faizan K.","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thenappan","family":"Chandrasekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardalan E.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Saskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miran","family":"Kenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olli","family":"Saarela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabbir M.H.","family":"Alibhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7339","key":"10.1016\/j.urolonc.2020.08.032_bib0001","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/bmj.324.7339.714","article-title":"Cancer chemoprevention","volume":"324","author":"Greenwald","year":"2002","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.032_bib0002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"New Eng J Med"},{"issue":"19","key":"10.1016\/j.urolonc.2020.08.032_bib0003","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.032_bib0004","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/pds.4702","article-title":"Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: an icelandic population-based case-control study","volume":"28","author":"Halfdanarson","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.urolonc.2020.08.032_bib0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.molmet.2019.04.003","article-title":"An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer","volume":"25","author":"Longo","year":"2019","journal-title":"Mol Metabol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.08.032_bib0006","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2012.07.054","article-title":"Synergistic killing effect of chloroquine and androgen deprivation in LNCaP cells","volume":"425","author":"Kaini","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.urolonc.2020.08.032_bib0007","unstructured":"Casey B. A DIABETES STRATEGY FOR CANADA - Report of the Standing Committee on Health. 2019. Available at: https:\/\/www.ourcommons.ca\/Content\/Committee\/421\/HESA\/Reports\/RP10365941\/hesarp23\/hesarp23-e.pdf. Accessed January 5, 2020."},{"issue":"16","key":"10.1016\/j.urolonc.2020.08.032_bib0008","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1503\/cmaj.150787","article-title":"Lifetime risk of diabetes among First Nations and non-First Nations people","volume":"188","author":"Turin","year":"2016","journal-title":"Can Med Assoc J"},{"issue":"15","key":"10.1016\/j.urolonc.2020.08.032_bib0009","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djt170","article-title":"Association between metformin use and risk of prostate cancer and its grade","volume":"105","author":"Margel","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"9131","key":"10.1016\/j.urolonc.2020.08.032_bib0010","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"Turner","year":"1998","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.032_bib0011","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"25","key":"10.1016\/j.urolonc.2020.08.032_bib0012","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","article-title":"Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes","volume":"31","author":"Margel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.032_bib0013","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41598-018-38285-w","article-title":"The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis","volume":"9","author":"He","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.urolonc.2020.08.032_bib0014","doi-asserted-by":"crossref","first-page":"e14955","DOI":"10.1097\/MD.0000000000014955","article-title":"Metformin use and prostate cancer risk: a meta-analysis of cohort studies","volume":"98","author":"Feng","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.urolonc.2020.08.032_bib0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.urolonc.2020.08.032_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2020.08.032_bib0017","unstructured":"Institute of Clinical Evaluative Sciences Homepage. 2019. Available at: http:\/\/www.ices.on.ca. Accessed January 5, 2020."},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.032_bib0018","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.juro.2016.11.002","article-title":"Prognostic significance of a negative prostate biopsy: an analysis of subjects enrolled in a prostate cancer screening trial","volume":"197","author":"Lewicki","year":"2017","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.urolonc.2020.08.032_bib0019","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.08.032_bib0020","unstructured":"Kralj B. Measuring rurality - RIO2008_BASIC: methodology and results. 2009. Available at: https:\/\/content.oma.org\/\/wp-content\/uploads\/2008rio-fulltechnicalpaper.pdf. Accessed January 5, 2020."},{"key":"10.1016\/j.urolonc.2020.08.032_bib0021","unstructured":"JHBSoP H. The Johns Hopkins ACG System- Excerpt from Technical Reference Guide Version 9.0. 2014. Available at: https:\/\/www.healthpartners.com\/ucm\/groups\/public\/@hp\/@public\/documents\/documents\/dev_057914.pdf. Accessed January 5, 2020."},{"issue":"11","key":"10.1016\/j.urolonc.2020.08.032_bib0022","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.032_bib0023","doi-asserted-by":"crossref","first-page":"298.e19","DOI":"10.1016\/j.urolonc.2019.01.030","article-title":"Population-based outcomes of men with a single negative prostate biopsy: importance of continued follow-up among older patients","volume":"37","author":"Sayyid","year":"2019","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.032_bib0024","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41391-018-0085-2","article-title":"The anticancer potential of metformin on prostate cancer","volume":"22","author":"Zaidi","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.urolonc.2020.08.032_bib0025","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1940-6207.CAPR-10-0175","article-title":"Metformin and other biguanides in oncology: advancing the research agenda","volume":"3","author":"Pollak","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"21","key":"10.1016\/j.urolonc.2020.08.032_bib0026","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.032_bib0027","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4161\/cc.8.1.7499","article-title":"The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells","volume":"8","author":"Vazquez-Martin","year":"2009","journal-title":"Cell cycle (Georgetown, Tex)"},{"key":"10.1016\/j.urolonc.2020.08.032_bib0028","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1038\/cddis.2011.86","article-title":"Metformin inhibits melanoma development through autophagy and apoptosis mechanisms","volume":"2","author":"Tomic","year":"2011","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.urolonc.2020.08.032_bib0029","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/carcin\/bgt307","article-title":"Metformin targets c-MYC oncogene to prevent prostate cancer","volume":"34","author":"Akinyeke","year":"2013","journal-title":"Carcinogenesis"},{"issue":"16","key":"10.1016\/j.urolonc.2020.08.032_bib0030","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/pros.23235","article-title":"Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells","volume":"76","author":"White-Al Habeeb","year":"2016","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.032_bib0031","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11934-017-0693-8","article-title":"Metformin and prostate cancer: a new role for an old drug","volume":"18","author":"Whitburn","year":"2017","journal-title":"Curr Urol Rep"},{"issue":"51","key":"10.1016\/j.urolonc.2020.08.032_bib0032","doi-asserted-by":"crossref","first-page":"e9427","DOI":"10.1097\/MD.0000000000009427","article-title":"Impact of metformin on serum prostate-specific antigen levels: data from the national health and nutrition examination survey 2007 to 2008","volume":"96","author":"Park","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.urolonc.2020.08.032_bib0033","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4236\/jct.2017.82007","article-title":"Statins and metformin use is associated with lower PSA levels in prostate cancer patients presenting for radiation therapy","volume":"8","author":"Liu","year":"2017","journal-title":"J Cancer Ther"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.032_bib0034","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/sj.bjc.6605188","article-title":"Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial","volume":"101","author":"Murtola","year":"2009","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.032_bib0035","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","article-title":"Metformin use and prostate cancer risk","volume":"66","author":"Preston","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.032_bib0036","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","article-title":"Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality","volume":"63","author":"Spratt","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.032_bib0037","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.juro.2018.06.031","article-title":"Metformin use is associated with improved survival for patients with advanced prostate cancer on androgen deprivation therapy","volume":"200","author":"Richards","year":"2018","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2020.08.032_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14689","article-title":"Association between antidiabetic medications and prostate-specific antigen levels and biopsy results","volume":"2","author":"Beckmann","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.032_bib0039","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.eururo.2014.01.040","article-title":"Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort","volume":"67","author":"Bhindi","year":"2015","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:23Z","timestamp":1761041963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920304014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1078143920304014"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.032","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The suggested chemopreventive association of metformin with prostate cancer in diabetic patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}